Zynteglo® (betibeglogene autotemcel) – New orphan drug approval
August 17, 2022 - The FDA announced the approval of bluebird bio’s Zynteglo (betibeglogene autotemcel), for the treatment of adult and pediatric patients with β-thalassemia who require regular red blood cell (RBC) transfusions.
Download PDF
